Lung Cancer, Small Cell
23
3
5
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.7%
2 terminated out of 23 trials
83.3%
-3.2% vs benchmark
9%
2 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (23)
Engagement of Veterans With Lung Cancer
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
Trial of NanoPac Intratumoral Injection in Lung Cancer
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
Regulatory Hycamtin(Oral) PMS
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population